The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) examine the clinical benefit of psilocybin as an adjunct to cognitive-behavioral therapy (CBT) for major depressive disorder. This study is a randomized, two-arm, fixed dose trial that will test the feasibility, acceptability, and participant and therapist adherence to PA-CBT. Both treatment arms will receive two doses of psilocybin (10mg and then 25mg, separated by one month). In Phase II, participants will be randomized (1:1) to either a 12-session PA-CBT or a 6-session standard psilocybin-assisted therapy (PAT) condition (3 hours of preparation plus 3 hours of supportive therapy integration following the psilocybin experiences).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
50
Participants will receive two doses of psilocybin (10mg, 25mg).
Twelve total sessions of therapy, including manualized cognitive behavioral therapy for major depressive disorder, including psychoeducation about depression, cognitive skills, and behavioral skills as well as preparation for psilocybin.
Six total therapy sessions. Preparation for psilocybin in the first three sessions plus supportive, nondirective psychotherapy in the final three sessions.
UCLA Semel Institute
Los Angeles, California, United States
RECRUITINGClient Satisfaction Questionnaire - 8
Treatment acceptability as measured by the participant. Total scores range from 8 to 32, with the higher number indicating greater satisfaction.
Time frame: 4-month treatment period
Retention/Attrition
Feasibility as measured by the number of participants retained in each treatment condition over the course of the study treatment
Time frame: 4-month treatment period
Hamilton Depression Rating Scale
symptom severity scored from 0-53, with larger values indicating greater depressive severity
Time frame: 7-month study period
Global Assessment of Functioning
psychosocial functioning scored from 0-100, with larger values indicating better functioning
Time frame: 7-month study period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.